IP Library Granted Patent US 11,723,954
Granted Patent B2
US 11,723,954 · App. 17/321,002 · Granted Aug 15, 2023

Therapeutic and cosmetic uses and applications of calreticulin

Inventors: Leslie I. Gold (New York, NY); Marek Michalak (Edmonton, CA)
Assignee: NEW YORK UNIVERSITY
A61K38/1738A61K8/0208A61K8/64A61K8/735A61Q7/00A61Q19/08A61K2800/91
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,723,954
App. No.
17/321,002
Granted
Aug 15, 2023
Kind
B2
Abstract

The invention relates to therapeutic and cosmetic uses of calreticulin including reducing eliminating wrinkles and/or fine lines, tissue repair and reconstruction, repairing damaged and/or cartilage, stimulating regeneration of an epidermal appendage, enhancing phagocytosis of bacteria by phagocytes within a wound, treating a wound in a patient suffering delayed wound healing, treating a corneal wound, and treating or preventing a surgical adhesion.

Claims (8)

1. A method of repairing damaged bone and/or cartilage in a patient in need thereof, which method comprises administering to the damaged bone and/or cartilage of the patient a therapeutically effective amount of calreticulin.

2. The method of claim 1 , wherein said calreticulin is administered by a route selected from the group consisting of topical, subcutaneous, intradermal, transdermal, and intracorporal.

3. The method of claim 1 , wherein said calreticulin is administered in an amount ranging between about 0.001 milligram and about 100 grams.

4. The method of claim 3 , wherein said calreticulin is administered in an amount ranging between about 0.001 milligram and about 50 milligrams.

5. The method of claim 1 , further comprising administering a cytokine, a growth factor, a glycosaminoglycan, a proteoglycan, syndecan or any mixtures thereof.

6. The method of claim 5 , wherein said glycosaminoglycan is hyaluronic acid.

7. The method of claim 5 , wherein said proteoglycan is perlecan or heparin sulfate.

8. The method of claim 5 , wherein said growth factor is selected from the group consisting of a platelet-derived growth factor, vascular endothelial growth factor, fibroblast growth factor, epidermal growth factor, transforming growth factor-beta, and any mixtures thereof.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 28, 2022
From: LESLIE I. GOLD
To: NEW YORK UNIVERSITY
Reel/Frame 061241/0133 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 28, 2022
From: MAREK MICHALAK
To: CALREGEN INC.
Reel/Frame 061243/0246 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 28, 2022
From: CALREGEN INC.
To: NEW YORK UNIVERSITY
Reel/Frame 061243/0714 →
CONFIRMATORY ASSIGNMENT Recorded Sep 28, 2022
From: GOLD, LESLIE I.
To: NEW YORK UNIVERSITY
Reel/Frame 061561/0666 →
Continuity (5)
Division 16291390 · Mar 4, 2019
Division 15004372 · Jan 22, 2016
Division 13717349
Provisional Application 61355987 · Jun 17, 2010
Related Publication 20210393739A1 · Dec 23, 2021